Philips has entered into an agreement to acquire SpectraWAVE, a developer of enhanced vascular imaging of coronary arteries, angiography-based physiology assessments, and the use of AI in medical imaging. The acquisition will expand Philips’ existing intravascular imaging and physiological assessment device portfolio to create a comprehensive offering in intravascular imaging and physiology solutions. SpectraWAVE’s intravascular imaging and physiological assessment technologies provide advanced solutions for the treatment of patients with coronary artery disease, the most frequent type of heart disease, affecting more than 300 million people worldwide. SpectraWAVE, based in Bedford, Massachusetts, was founded in 2017 and currently employs more than 70 people. A clinician utilizing Philips’ IntraSight and Azurion technologies. Courtesy of Philips. SpectraWAVE's technologies include its HyperVue Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1-FFR, an AI-enabled angio-based fractional flow reserve technology that delivers rapid, accurate coronary physiology assessment from a single angiogram. “We are doubling down on image-guided therapy and expanding our portfolio in the coronary intervention segment with the addition of SpectraWAVE’s AI-powered innovations in high-definition intravascular imaging and angio-based physiological assessment, enabling us to deliver better care for more people,” said Roy Jakobs, CEO of Royal Philips. The Philips Azurion image-guided therapy platform has been steadily integrating the company’s advanced diagnostic and treatment devices to support a wide range of procedures across interventional radiology, neuroradiology and vascular surgery. “This partnership allows us to integrate and scale HyperVue and X1-FFR into the world’s leading image-guided therapy ecosystem, expanding choice for clinicians and supporting more consistent, high-quality care for the millions of patients who depend on coronary intervention each year,” said Eman Namati, CEO of SpectraWAVE. Earlier this fall, SpectraWave appointed Jonathan Hill chief medical officer. Hill is an interventional cardiologist from Royal Brompton Hospital in London, with extensive expertise in coronary artery disease, complex percutaneous coronary intervention, intravascular imaging, physiology, cardiovascular innovation, and clinical study design and implementation. The company also appointed a new CFO and chief commercial officer this year, and, in 2024, closed a $50 million funding round led by Johnson & Johnson Innovation.